In the patients with Glanzmann thrombasthenia (22, 23) and acute myeloid leukemia (24), low levels of the CD41-CD61 complex resulted in reduced platelet aggregation and thereby, increased bleeding disorders. Here, ITGA2B is linked to hemorrhagic disease.